AIM ImmunoTech (NYSE:AIM – Get Rating) and Icosavax (NASDAQ:ICVX – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk. Institutional and Insider Ownership 15.6% of AIM ImmunoTech shares are […]